相关实验视频

Updated: Mar 11, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

多原子分析定义了三种不同的尿癌分子亚型,对精密治疗有意义

Nils C H van Creij¹, Piotr Tymoszuk², Florian Handle³

¹Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria.

Clinical and translational medicine

|March 10, 2026

概括

这项研究引入了尿路细胞癌 (UC) 的新分子分类,确定了具有独特预后和治疗脆弱性的三个不同的群体. 这一框架有助于个性化风险评估和膀癌的治疗策略.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
分子生物学分子生物学

背景情况:

尿路细胞癌 (UC) 是一种异质的癌症,其分子分类在临床实践中有限.
精确瘤学的努力需要在UC中进行转录基因和蛋白质基因数据分析的强大框架.

研究的目的:

使用转录组和蛋白组数据开发尿癌 (UC) 的分子分类框架.
确定不同分子亚型的非肌肉侵入性膀癌 (NMIBC) 和肌肉侵入性膀癌 (MIBC).
为每个已识别的分子集群提出量身定制的治疗策略.

主要方法:

利用整个转录组的自我组织地图和4439个NMIBC/MIBC转录组和蛋白质组的规范化半监督聚类,以及33个UC细胞系.
集成的in silico和in vitro方法来验证分子特征并预测治疗反应.
在泌尿腺癌中确定了三种不同的分子.

主要成果:

确定了三个分子UC集群,每个都有独特的mRNA,蛋白质,生物过程,新陈代谢和驱动基因特征.
集群表现出不同的预后和预测的治疗脆弱性/耐药性.
集群#1 (高风险,富含斯特罗玛) 建议使用细胞毒药物,铁灭诱导剂,PARP抑制剂. 集群#2 (侵略性,免疫透性) 拟议的细胞毒剂,EGFR/ERBB,MEK/ERK抑制剂. 集群#3 (低风险,光线) 表示表观遗传药物,EGFR/FGFR抑制剂.

结论:

针对UC的新型分子分类学为风险分层和临床试验设计提供了实际框架.
这种分类有助于个性化,基于转录基因和蛋白质基因的风险评估和UC的治疗开发.
适用于NMIBC和MIBC的三个经过验证的UC集群提供了不同的预后和治疗特征.

关键词:

膀癌:膀癌是一种癌症.药物反应药物反应分子分类的分子分类.蛋白质组学蛋白质组学翻译学翻译学翻译学翻译学

更多相关视频

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...